Biological and Pharmaceutical Bulletin · 2003 · 29 citations · 21 references
MedicinePharmacologyToxicologyExperimental PharmacologyFruit ScienceHepatic PharmacokineticsCytochrome P450 EnzymesCytochrome P450-mediated MetabolismFruit BiochemistryFruit PhysiologyCitrus FruitsCytochrome P450 Enzyme ActivityCytochrome P450 Enzyme InhibitionCytochrome P450 Human Liver MicrosomesCytochrome P450 InhibitionFruit Juice ConsumptionMicrosomal Incubation AssaysMouse Liver Microsomes
The capacities of citrus fruits to inhibit midazolam 1'-hydroxylase activity of cytochrome P450 3A (CYP3A) expressed in human liver microsomes were evaluated. Eight citrus fruits such as ama-natsu, banpeiyu, Dekopon, hassaku, hyuga-natsu, completely matured kinkan (Tamatama), takaoka-buntan and unshu-mikan were tested. We also examined the inhibition of CYP3A activity by grapefruit (white) and grapefruit juice (white, Tropicana-Kirin). The addition of a fruit juice prepared from banpeiyu, hassaku, takaoka-buntan or Tamatama caused the inhibition of the microsomal CYP3A activity. The inhibition depended on the amount of a fruit juice added to the incubation mixture (2.5 and 5.0%, v/v). The fruit juice from banpeiyu showed the most potent inhibition of CYP3A. The addition of a banpeiyu juice (5.0%, v/v) resulted in the inhibition of midazolam 1'-hydroxylase activity to about 20% of control without a fruit juice. The elongation of the preincubation period of a fruit juice from banpeiyu (5.0%, v/v) with the microsomal fraction (5 to 15 min) led to the enhancement of the CYP3A inhibition (5% of control). Thus, we discovered ingredients of banpeiyu to be inhibitor(s) or mechanism-based inhibitor(s) of human CYP3A activity, but the inhibitory effects of them were somewhat lower than those of grapefruit.
21
Interaction of citrus juices with felodipine and nifedipine
Dg Bailey, J. David Spence, Claudio Munoz et al. · The Lancet · 1991 · 592 citations
Interaction between grapefruit juice and midazolam in humans*
Hugo Kupferschmidt, Huy Riêm Ha, Walter Ziegler et al. · Clinical Pharmacology & Therapeutics · 1995 · 361 citations